Watch Demo

South Korea Antihypertensive Industry Outlook 2022 - 2026

See how South Korea Antihypertensive performed compared to key markets such as Germany, Italy and Spain.

Key Market Indicators

Sales of Korean antihypertensive medicines are set to reach nearly $37 million by 2026, according to recent projections. This represents a 1.1 percent annual growth since 2021, when sales were at $35 million. Since 2013, demand for antihypertensive medicines in Korea has been increasing at 6.4 percent every year. In 2021, the country ranked 12th in global sales, though the Czech Republic overtook it with $35 million in sales. Italy, Spain and Australia came in second, third and fourth respectively.

South Korea Antihypertensive Market Data and Forecasts

How much will South Korea Antihypertensive Market grow to 2026?

Forecast: Renin-Angiotensin System Medicine Sales in South Korea
Forecast: Antihypertensive Medicine Use in South Korea
Forecast: Antihypertensive Medicine Sales in South Korea
Forecast: Renin-Angiotensin System Medicine Sales in South Korea
Forecast: Antihypertensive Medicine Sales in South Korea
More in Antihypertensive Industry for 2027

Improve your Knowledge with the latest Indicators and Trends